Lilly announces plan to expand global access to health care
pharmafile | October 19, 2016 | News story | Research and Development | Eli Lilly, Lilly 30x30, global health
Eli Lilly has announced a project, known as Lilly 30×30, which is a five-year, $90 million investment to improve access to treatments for diabetes, cancer and tuberculosis. The aim of the project being to reach 30 million people in resource-limited settings annually by 2030 with improved access to aforementioned treatments.
The work will see them expand current operations in Brazil, China, India, Kenya, Mexico, Russia South Africa and the US. Lilly will explore new approaches within different areas of its business, including: “initiatives to strengthen health systems and local treatment capacity in communities with significant gaps in care; patient education programs; collaboration on drug discovery for diseases disproportionately affecting people in resource-limited settings; product delivery and packaging more appropriate for people in resource-limited settings and innovative business models, including alternative product pricing strategies to improve access to care.”
Speaking on the project, John C. Lechleiter, Ph.D., Lilly chairman, president and CEO, stated: “Over the last two decades, we have made tremendous progress in expanding access to quality care in poorer communities, but we can and must do more. Lilly 30×30 is a company-wide mandate to achieve a six-fold increase in the number of people we reach annually, outside of our traditional business,” said John C. Lechleiter, Ph.D., Lilly chairman, president and CEO.
Lechleiter continued, “We will engage the entire Lilly organization to ensure that our aspirational goals are met. The investments announced today will help millions more benefit from Lilly’s life-saving work and accelerate our contributions toward the U.N. Sustainable Development Goals.”
Ben Hargreaves
Related Content
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …
